0001376793 2025-07-01 2026-06-30 0001376793 2025-12-31 0001376793 2026-09-28 0001376793 2026-06-30 0001376793 2025-06-30 0001376793 2024-07-01 2025-06-30 0001376793 us-gaap:CommonStockMember 2024-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001376793 us-gaap:RetainedEarningsMember 2024-06-30 0001376793 2024-06-30 0001376793 us-gaap:CommonStockMember 2025-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001376793 us-gaap:RetainedEarningsMember 2025-06-30 0001376793 us-gaap:CommonStockMember 2024-07-01 2025-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2025-06-30 0001376793 us-gaap:RetainedEarningsMember 2024-07-01 2025-06-30 0001376793 us-gaap:CommonStockMember 2025-07-01 2026-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2026-06-30 0001376793 us-gaap:RetainedEarningsMember 2025-07-01 2026-06-30 0001376793 us-gaap:CommonStockMember 2026-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001376793 us-gaap:RetainedEarningsMember 2026-06-30 0001376793 us-gaap:SubsequentEventMember CVAT:TenderOfferAgreementMember 2026-08-13 2026-08-14 0001376793 CVAT:DesmetMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2026-06-30 0001376793 CVAT:DesmetMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2025-06-30 0001376793 CVAT:VendorOneMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2026-06-30 0001376793 CVAT:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2026-06-30 0001376793 CVAT:VendorOneMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2025-06-30 0001376793 CVAT:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2025-06-30 0001376793 CVAT:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2026-06-30 0001376793 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-06-30 0001376793 us-gaap:WarrantMember 2025-07-01 2026-06-30 0001376793 us-gaap:WarrantMember 2024-07-01 2025-06-30 0001376793 CVAT:ConvertibleNoteMember 2025-07-01 2026-06-30 0001376793 CVAT:ConvertibleNoteMember 2024-07-01 2025-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:NanoReactorsMember CVAT:TLAAgreementMember 2025-07-01 2026-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:NanoReactorsMember CVAT:TLAAgreementMember 2024-07-01 2025-06-30 0001376793 CVAT:DesmetMember CVAT:PatentAssignmentAndLicenseBackAgreementMember 2024-10-08 2024-10-09 0001376793 CVAT:DesmetMember CVAT:PatentAssignmentAndLicenseBackAgreementMember 2024-07-01 2025-06-30 0001376793 CVAT:BridgeNotePayableMember 2026-06-30 0001376793 CVAT:BridgeNotePayableMember 2025-06-30 0001376793 CVAT:BridgeNotePayableMember 2026-05-11 0001376793 CVAT:BridgeNotePayableMember 2026-05-10 2026-05-11 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2026-10-29 2026-10-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2026-11-29 2026-11-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2026-12-29 2026-12-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-01-29 2027-01-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-02-27 2027-02-28 0001376793 srt:ChiefExecutiveOfficerMember 2026-01-09 2026-05-04 0001376793 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001376793 us-gaap:ConvertibleNotesPayableMember 2025-06-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2026-01-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2025-07-01 2026-06-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2026-06-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2026-12-05 0001376793 2025-11-30 0001376793 2025-12-01 2026-06-30 0001376793 us-gaap:MeasurementInputSharePriceMember 2025-07-01 2026-06-30 0001376793 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-07-01 2026-06-30 0001376793 us-gaap:MeasurementInputPriceVolatilityMember 2025-07-01 2026-06-30 0001376793 us-gaap:MeasurementInputExpectedTermMember 2025-07-01 2026-06-30 0001376793 CVAT:MeasurementInputNumberOfSharesIssuableMember 2025-07-01 2026-06-30 0001376793 CVAT:EIDLMember 2026-06-30 0001376793 CVAT:EIDLMember 2025-06-30 0001376793 CVAT:EIDLMember 2020-07-01 2020-07-31 0001376793 CVAT:EIDLMember 2020-07-31 0001376793 us-gaap:SeriesAPreferredStockMember 2026-06-30 0001376793 us-gaap:SeriesBPreferredStockMember 2026-06-30 0001376793 us-gaap:WarrantMember 2025-07-01 2026-06-30 0001376793 us-gaap:WarrantMember 2026-06-30 0001376793 CVAT:SettlementOfAccruedPayrollMember 2025-02-01 2025-02-28 0001376793 CVAT:ConsultingServicesMember 2025-06-09 2025-06-10 0001376793 CVAT:CertainWarrantHoldersMember us-gaap:WarrantMember CVAT:CashlessExerciseOfWarrantsMember 2025-11-24 2025-11-25 0001376793 CVAT:CertainWarrantHoldersMember CVAT:CashlessExerciseOfWarrantsMember us-gaap:CommonStockMember 2025-11-24 2025-11-25 0001376793 us-gaap:WarrantMember 2024-11-30 0001376793 us-gaap:WarrantMember 2025-02-28 0001376793 srt:MinimumMember us-gaap:WarrantMember 2024-11-30 0001376793 srt:MinimumMember us-gaap:WarrantMember 2025-02-28 0001376793 srt:MaximumMember us-gaap:WarrantMember 2024-11-30 0001376793 srt:MaximumMember us-gaap:WarrantMember 2025-02-28 0001376793 CVAT:BlackScholesOptionMember 2024-11-30 0001376793 CVAT:BlackScholesOptionMember 2025-02-28 0001376793 srt:MinimumMember CVAT:BlackScholesOptionMember 2024-11-30 0001376793 srt:MinimumMember CVAT:BlackScholesOptionMember 2025-02-28 0001376793 srt:MaximumMember CVAT:BlackScholesOptionMember 2024-11-30 0001376793 srt:MaximumMember CVAT:BlackScholesOptionMember 2025-02-28 0001376793 srt:MinimumMember CVAT:BlackScholesOptionMember 2024-11-01 2024-11-30 0001376793 srt:MinimumMember CVAT:BlackScholesOptionMember 2025-02-01 2025-02-28 0001376793 srt:MaximumMember CVAT:BlackScholesOptionMember 2024-11-01 2024-11-30 0001376793 srt:MaximumMember CVAT:BlackScholesOptionMember 2025-02-01 2025-02-28 0001376793 CVAT:BlackScholesOptionMember 2024-11-01 2024-11-30 0001376793 CVAT:BlackScholesOptionMember 2025-02-01 2025-02-28 0001376793 CVAT:WarrantsMember CVAT:SettlementOfAccruedPayrollMember 2025-02-01 2025-02-28 0001376793 us-gaap:WarrantMember 2024-06-30 0001376793 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001376793 us-gaap:WarrantMember 2024-07-01 2025-06-30 0001376793 us-gaap:WarrantMember 2025-06-30 0001376793 CVAT:WarrantPrice1Member 2026-06-30 0001376793 CVAT:WarrantPrice1Member 2025-07-01 2026-06-30 0001376793 CVAT:WarrantPrice2Member 2026-06-30 0001376793 CVAT:WarrantPrice2Member 2025-07-01 2026-06-30 0001376793 CVAT:WarrantPrice3Member 2026-06-30 0001376793 CVAT:WarrantPrice3Member 2025-07-01 2026-06-30 0001376793 CVAT:WarrantPrice4Member 2026-06-30 0001376793 CVAT:WarrantPrice4Member 2025-07-01 2026-06-30 0001376793 CVAT:WarrantPrice5Member 2026-06-30 0001376793 CVAT:WarrantPrice5Member 2025-07-01 2026-06-30 0001376793 CVAT:WarrantPrice6Member 2026-06-30 0001376793 CVAT:WarrantPrice6Member 2025-07-01 2026-06-30 0001376793 us-gaap:WarrantMember 2026-06-30 0001376793 us-gaap:WarrantMember 2025-07-01 2026-06-30 0001376793 us-gaap:DomesticCountryMember 2025-07-01 2026-06-30 0001376793 us-gaap:DomesticCountryMember 2024-07-01 2025-06-30 0001376793 CVAT:SettlementOfAccruedPayrollMember 2025-02-28 0001376793 CVAT:BoardMemberMember 2024-07-01 2025-06-30 0001376793 CVAT:DirectorsAndOfficersMember 2025-07-01 2026-06-30 0001376793 us-gaap:AllOtherSegmentsMember 2025-07-01 2026-06-30 0001376793 us-gaap:AllOtherSegmentsMember 2024-07-01 2025-06-30 0001376793 2026-04-01 2026-06-30 iso4217:USD shares iso4217:USD shares pure CVAT:Integer false 2026 FY 0001376793

P5Y

10-K true false 2026-06-30 --06-30 000-53239 Cavitation Technologies, Inc. NV 20-4907818 10019 CANOGA AVENUE CHATSWORTH CA 91311 818 718-0905 Common Stock, $0.001 par value No No Yes Yes Non-accelerated Filer true false false false false 14600418 323820459 Risk management and strategy The manner in which we store and/or transmit sensitive data in connection with our research and development and our day-to-day operations is an important part of how we operate and plan to operate. We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees and violation of data privacy or security laws. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250701__20260630_zx4c74VwIqc3">Identifying and assessing cybersecurity risk is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250701__20260630_zLvyjdRFFZ9f">integrated into our overall risk management systems and processes. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250701__20260630_zf7KtA9HGoa5">Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified through review by our internal information technology governance, risk and compliance policies. To defend, detect and respond to cybersecurity incidents, we, among other things: may conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement appropriate changes. Our risk management program also assesses <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250701__20260630_z7U3qEuSXq9g">third party risks, and we perform third-party risk management to identify and mitigate risks from our vendors, suppliers, and other business partners associated with our use of third-party service providers. Cybersecurity risks are evaluated when determining the selection and oversight of applicable <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250701__20260630_z7kzbNZ01K1h">third-party service providers and potential fourth-party risks when handling and/or processing our employee, business or customer data. Identifying and assessing cybersecurity risk is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250701__20260630_zLvyjdRFFZ9f">integrated into our overall risk management systems and processes. true Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified through review by our internal information technology governance, risk and compliance policies. To defend, detect and respond to cybersecurity incidents, we, among other things: may conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement appropriate changes. true true Governance overview <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250701__20260630_z4qhN9vZ1gi8">Due to the nature of our operation and the limited number of personnel and management, we do not have a dedicated cyber leadership role. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20250701__20260630_zI1YZbZORLb4">Our principal executive officer is involved in all aspects of our operations and will report any cybersecurity instances to the board of directors. Third parties outside of the entity will be used in any remediation efforts of required. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250701__20260630_zjvDRWFVISN4">We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250701__20260630_zdE5FOoo4QP4">not experienced any historical cyber incidents. Due to the nature of our operation and the limited number of personnel and management, we do not have a dedicated cyber leadership role. Our principal executive officer is involved in all aspects of our operations and will report any cybersecurity instances to the board of directors. Third parties outside of the entity will be used in any remediation efforts of required. We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250701__20260630_zdE5FOoo4QP4">not experienced any historical cyber incidents. false 572 Weinberg & Company, P.A. Los Angeles, California

17000

249000

10000

17000

27000

34000

286000

1000

10000

45000

297000

174000

75000

19000

3000

129000

103000

115000 0

34000

14000

588000

78000

150000

738000

228000

0.001

10000000

0.001

1000000000

317220739

289156340

317000

289000

27354000

26740000

-28364000

-26960000

-693000

69000

45000

297000

3000

203000

-0

38000

3000

165000

1380000

1057000

11000

95000

1391000

1152000

-1388000

-987000

880000

-40000

-6000

24000

-1404000

-113000

-0.00

303333883

286001131

284289740

284000

26083000

-26847000

-480000

200000

6000

4666600

5000

185000

190000

195000

271000

-113000

289156340

289000

26740000

-26960000

69000

8269399

8000

240000

248000

8300000

8000

386000

394000

11495000

12000

-12000

-1404000

317220739

317000

27354000

-28364000

-693000

-1404000

-113000

15000

24000

-0

195000

394000

6000

-0

880000

-10000

10000

-10000

11000

42000

99000

129000

11000

16000

-46000

-755000

-806000

880000

60000

248000

115000

100000

-0

4000

523000

-4000

-232000

70000

249000

179000

17000

249000

9000

6000

38000 0 0 190000 0 271000

<p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zMW0Qae5eQn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 1 – Organization and Summary of Significant Accounting Policies Cavitation Technologies, Inc. (“the Company,” “CTi,” “we,” “us,” “CVAT,” and “our”) is a Nevada corporation originally incorporated in January 2007 under the name Bio Energy, Inc. The Company had originally developed, patented, and commercialized proprietary technology, which has subsequently been sold to Desmet Ballestra in October 2024, pursuant to a patent assignment and license back agreement. On August 9, 2025, the Company incorporated a wholly owned subsidiary, Xyra Corp. (“Xyra”). Xyra will be focused on identifying and capitalizing on opportunities in the crypto technologies market. Xyra holds an exclusive license for Cavitation Technologies Inc. patented Cavitation Non-Thermal Plasma™ (CNTP) systems, developed initially for immersion cooling in crypto mining and high-density data centers. Tender Offer On August 14, 2026 the Company entered into a definitive tender offer agreement (the “Agreement”) with European Guarantee Services S.à.r.l. (“Purchaser”), pursuant to which the Purchaser agreed to acquire or seek to acquire all of the outstanding shares of common stock of Company (the “CTI Shares”) for a total purchase price of $<span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20260813__20260814__us-gaap--TypeOfArrangementAxis__custom--TenderOfferAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2EAcsX5oKvg" title="Purchase price">35 million in cash (less certain indebtedness and accrued liabilities of the Company) (the “Net Price”). Under the Agreement, the Purchaser will commence an offer to purchase the CTI Shares (the “Offer”) within 10 business days after the TO has met the regulatory requirements of the SEC and will remain open during an offer period of at least 60 business days to give shareholders an opportunity to review this Agreement, the Offer and the offer documents. Under the Agreement, the Offer will contain an Initial Offer Price per Share determined by dividing the Net Price by the total number of CTI Shares outstanding as of the date of the Agreement. However, the Initial Offer Price will be subject to adjustment and a Final Offer Price per Share will be determined based on the total number of CTI Shares outstanding as of a Record Date, a date that is 45 business days after the commencement of the Offer. The Final Offer Price will be included in an amended Offer and offer documents that will be filed with the SEC and disseminated to shareholders of the Company. Following a determination of the Final Offer Price and dissemination of the amended Offer to the Company’s shareholders, the Purchaser will extend the offer period as may be necessary in order to give shareholders at least 30 business days to review the amended Offer, the Final Offer Price, and a final recommendation issued by Company’s board of directors before the offer period during which shareholders may tender their Shares pursuant to the amended Offer (as extended) expires. The Agreement contains both customary and special customary representations, and warranties of the parties and sets forth, in Annex I to the Agreement, a list of the conditions (the “Offer Conditions”) that must be satisfied or waived by Purchaser before the Purchaser becomes obligated to purchase Shares that are tendered pursuant to the amended Offer. These Offer Conditions may be summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">1.</td> <td style="width: 94%; text-align: justify">Purchaser will have acquired shares of common stock of Alchemy Beverages Inc. (“ABI”), a private Delaware corporation in which the Company owns about 17% of the outstanding shares of common stock in ABI (the “ABI Shares”), pursuant to a separate tender offer that will be made by Purchaser for ABI Shares under a separate tender offer agreement executed between ABI and Purchaser;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>2.</td> <td style="text-align: justify">Shareholders of the Company will have tendered a sufficient number of CTI Shares to the amended Offer that will enable Purchaser, together with any CTI Shares previously purchased by Purchaser and its affiliates or investors, to acquire at least 90% of the CTI Shares outstanding as of the Record Date;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>3.</td> <td style="text-align: justify">No action has been taken by any government entity to restrain or prohibit the consummation of Purchaser’s acquisition of CTI Shares tendered pursuant to the amended Offer;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="text-align: justify; width: 3%">4.</td> <td style="text-align: justify; width: 94%">No termination of the Agreement in accordance with the terms thereof will have occurred;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">5.</td> <td style="text-align: justify">The representations and warranties given by the Company as of the date of the Agreement shall be true and correct, and Company will have performed its covenants under the Agreement, in each case for any discrepancy or failure that, individually or in the aggregate, will not have a material adverse effect on the transaction;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">6.</td> <td style="text-align: justify">No adverse material effect, as defined in the Agreement, will have occurred; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">7.</td> <td style="text-align: justify">The Parties will have submitted this Agreement, the offer documents and other information to the Committee on Foreign Investment in the United States (“CFIUS”) for review in accordance with U.S. laws and regulations and CFIUS, upon the conclusion of the review period, or any investigation into the transaction, will have taken adverse action to block the transactions under the Agreement.</td></tr> </table> Following the expiration of the offer period (as may be extended), and subject to the satisfaction, or waiver by Purchaser, of the Offer Conditions, the Agreement provides that Purchaser will acquire, at the Final Offer Price, all of the outstanding CTI Shares that are tendered pursuant to the amended Offer (and not validly withdrawn). Neither this Agreement nor the cash tender offer for the CTI Shares that will be made by Purchaser under the terms of the Agreement will require the prior approval of the shareholders of Company. The proposed transaction remains subject to regulatory review and approval and has not yet been finalized or consummated. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2026, the Company incurred net loss of $1,404,000, used cash in operations of $755,000 and as of June 30, 2026, the Company had a stockholders’ deficit of $693,000. In addition, the Company has had a history of operating losses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from its inability to continue as a going concern. As of June 30, 2026, the Company has cash in the amount of $17,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by using its Reserved Grant Back License to apply the technology to; (i) water and wastewater processing, recovery, recycling and purification (including oilfield wastewater) and (ii) manufacture, distillation, brewing, enhancements, sale and marketing of alcoholic beverages, together the Licensed Fields. The Company has a worldwide, exclusive, transferable and royalty-free license and right to design, build, use, export, improve, sell and market Nano Reactor® devices and systems (and products) that incorporate or utilize Nano Reactor® devices, in each case within the Licensed Fields, and to continue to use the Nano Reactor® trademark in connection with its business, systems and products within the Licensed Fields. In addition, the Company will continue to develop its (i) water treatment and remediation in the Permian Basin; (ii) water remediation and disinfection in agriculture; (iii) business venture with Alchemy Beverages, Inc. to develop a smart home kitchen appliance for alcoholic beverages; (iv) hydro plasma technology, and (v) non thermal plasma for immersion cooling in crypto mining and high-density data centers, in order to generate revenues and sustain operations. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company does not believe it has enough cash and access to cash to sustain operations through June 2027. The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations. Principles of Consolidation The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiaries Hydrodynamic Technology, Inc and Xyra Corp. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include valuation of our equity method investments, and derivative liabilities, assumptions used in valuing our stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates. Revenue Recognition The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. For the license fee revenue, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement and collectability is certain. The Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer and collectability is certain. In addition, the Company also recognizes revenues from short term rental of nano reactors. Rental revenue is recognized over the term of the agreement and when collectability is certain. During the year ended June 30, 2026, the Company recognized revenues of $3,000 pursuant to a short-term rental agreement with a customer. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. The Company uses Level 3 inputs for its valuation methodology for the derivative liabilities as their fair values were determined by using a variable option pricing model. The Company’s derivative liabilities are adjusted to reflect fair value at each reporting date, with any increase or decrease in the fair value being recorded in the statement of operations. Fair Value Measurement FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. As of June 30, 2026 and June 30, 2025, the carrying value of certain accounts such as accounts receivable, accounts payable, accrued expenses and accrued payroll approximate their fair value due to the short-term nature of such instruments. The carrying value of our note payable approximate their fair value due to interest rate of the note. The Company’s derivative liabilities at June 30, 2026 were determined using level 3 inputs. Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2026 and 2025, the Company had no cash equivalents. The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000. As of June 30, 2026, Company had no deposits in excess of federally insured limits. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of its financial institutions. Accounts receivable and allowance for credit losses Trade accounts receivable are recorded at the invoiced amount, do not bear interest, and are generally unsecured with payment terms ranging from 30 to 60 days. The allowance for credit losses is a valuation account deducted from the amortized cost basis of trade accounts receivable to present the net amount expected to be collected. Management estimates lifetime expected credit losses upon initial recognition of the receivable, rather than waiting for a loss event to occur. The allowance is updated at each reporting date, with changes recognized immediately in earnings as credit loss expense (within selling, general, and administrative expenses). Write-Off Policy Trade receivables are written off against the allowance when management determines that the balance is fully uncollectible. Indicators of uncollectability include the exhaustion of standard corporate collection efforts, a customer's cessation of business operations, or a formal legal determination. Subsequent recoveries of amounts previously written off are credited to the allowance. Equity Method Investment The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of June 30, 2026 and 2025, the remaining de minimus value of its investments was $1,000, respectively. Income Taxes The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates as of the date of enactment. Leases The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Leases with an initial term of 12 months or less are not recorded on the balance sheet. In January 2025, the lease agreement expired and is currently on a month-to-month basis. Total lease expense recorded for the years ended June 30, 2026 and 2025 amounted to $36,000 and $29,000, respectively and is reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations. Share-Based Compensation We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. Advertising Costs Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $12,000 and $16,000 for the years ended June 30, 2026 and 2025 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations. Research and Development Costs Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees related to the Company’s cold plasma technology, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2026 and 2025 amounted to $11,000 and $95,000, respectively. Warranty Policy The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2026 and 2025. Net Loss Per Share The Company’s computation of net loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. There were no adjustments to net loss required for purposes of computing diluted earnings per share. At June 30, 2026 and 2025 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive as the exercise price of these warrants were greater than the stock price of the Company common stock. <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2tVDMl7Bn1e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of anti-dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLBDTQ6EXzJl" style="width: 13%; text-align: right" title="Antidilutive shares">31,571,784</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk3u5emk06Fd" style="width: 13%; text-align: right" title="Antidilutive shares">49,041,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zPfP2rUkiHb9" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">1,295,639</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zRuectThUzZi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630_zWoH5rANeOHc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">32,867,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240701__20250630_zSq2RR3ASHj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">49,041,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Concentrations During the year ended June 30, 2026 we recorded <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetMember_z9wRZ89lJ97c" title="Concentration risk percentage">100% of our revenue from one rental customer and for the year ended June 30, 2025 we recorded <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetMember_zMlqkjmmxg8h" title="Concentration risk percentage">98% of our revenue from Desmet Ballestra (Desmet) (see Note 2). As of June 30, 2026, two vendors accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zA0lb0D0sRl7" title="Concentration risk, percentage">18% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z4NEyec7TjTa" title="Concentration risk, percentage">15% of the Company’s accounts payable. As of June 30, 2025, two vendors accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zqTT6qNdn6Jj" title="Concentration risk, percentage">18% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z8LQm1Mucpvg" title="Concentration risk, percentage">7% of the Company’s accounts payable. At June 30, 2026, we had no receivables. As of June 30, 2025, one customer accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zk4CX9NCSeU1" title="Concentration risk, percentage">100% of the Company’s accounts receivable. Segments The Company operates in one segment for the development and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s Chief Operating Decision Maker (CODM) has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base, single sales team, marketing department, customer service department, operations department, finance and accounting department to support its operations and similarities in economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in Note 12. Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements. Reclassification of prior year presentation As of June 30, 2026, the Company reclassified $15,000 of accrued interest, which was previously included in accounts payable and accrued expenses at June 30, 2025, to note payable – non-current. In addition, $3,000 of accrued interest that was previously included in accounts payable and accrued expenses was reclassified to accrued interest payable in the current-year presentation. These reclassifications were made to conform the prior-year amounts to the current-year presentation and had no effect on total liabilities, net loss, or stockholders’ equity (deficit).

35000000

Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2026, the Company incurred net loss of $1,404,000, used cash in operations of $755,000 and as of June 30, 2026, the Company had a stockholders’ deficit of $693,000. In addition, the Company has had a history of operating losses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from its inability to continue as a going concern. As of June 30, 2026, the Company has cash in the amount of $17,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by using its Reserved Grant Back License to apply the technology to; (i) water and wastewater processing, recovery, recycling and purification (including oilfield wastewater) and (ii) manufacture, distillation, brewing, enhancements, sale and marketing of alcoholic beverages, together the Licensed Fields. The Company has a worldwide, exclusive, transferable and royalty-free license and right to design, build, use, export, improve, sell and market Nano Reactor® devices and systems (and products) that incorporate or utilize Nano Reactor® devices, in each case within the Licensed Fields, and to continue to use the Nano Reactor® trademark in connection with its business, systems and products within the Licensed Fields. In addition, the Company will continue to develop its (i) water treatment and remediation in the Permian Basin; (ii) water remediation and disinfection in agriculture; (iii) business venture with Alchemy Beverages, Inc. to develop a smart home kitchen appliance for alcoholic beverages; (iv) hydro plasma technology, and (v) non thermal plasma for immersion cooling in crypto mining and high-density data centers, in order to generate revenues and sustain operations. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company does not believe it has enough cash and access to cash to sustain operations through June 2027. The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

-1404000

-755000

-693000

17000

Principles of Consolidation The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiaries Hydrodynamic Technology, Inc and Xyra Corp. Intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include valuation of our equity method investments, and derivative liabilities, assumptions used in valuing our stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.

Revenue Recognition The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. For the license fee revenue, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement and collectability is certain. The Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer and collectability is certain. In addition, the Company also recognizes revenues from short term rental of nano reactors. Rental revenue is recognized over the term of the agreement and when collectability is certain. During the year ended June 30, 2026, the Company recognized revenues of $3,000 pursuant to a short-term rental agreement with a customer.

Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. The Company uses Level 3 inputs for its valuation methodology for the derivative liabilities as their fair values were determined by using a variable option pricing model. The Company’s derivative liabilities are adjusted to reflect fair value at each reporting date, with any increase or decrease in the fair value being recorded in the statement of operations.

Fair Value Measurement FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. As of June 30, 2026 and June 30, 2025, the carrying value of certain accounts such as accounts receivable, accounts payable, accrued expenses and accrued payroll approximate their fair value due to the short-term nature of such instruments. The carrying value of our note payable approximate their fair value due to interest rate of the note. The Company’s derivative liabilities at June 30, 2026 were determined using level 3 inputs.

Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2026 and 2025, the Company had no cash equivalents. The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000. As of June 30, 2026, Company had no deposits in excess of federally insured limits. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of its financial institutions.

Accounts receivable and allowance for credit losses Trade accounts receivable are recorded at the invoiced amount, do not bear interest, and are generally unsecured with payment terms ranging from 30 to 60 days. The allowance for credit losses is a valuation account deducted from the amortized cost basis of trade accounts receivable to present the net amount expected to be collected. Management estimates lifetime expected credit losses upon initial recognition of the receivable, rather than waiting for a loss event to occur. The allowance is updated at each reporting date, with changes recognized immediately in earnings as credit loss expense (within selling, general, and administrative expenses). Write-Off Policy Trade receivables are written off against the allowance when management determines that the balance is fully uncollectible. Indicators of uncollectability include the exhaustion of standard corporate collection efforts, a customer's cessation of business operations, or a formal legal determination. Subsequent recoveries of amounts previously written off are credited to the allowance.

Equity Method Investment The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of June 30, 2026 and 2025, the remaining de minimus value of its investments was $1,000, respectively.

1000

Income Taxes The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates as of the date of enactment.

Leases The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Leases with an initial term of 12 months or less are not recorded on the balance sheet. In January 2025, the lease agreement expired and is currently on a month-to-month basis. Total lease expense recorded for the years ended June 30, 2026 and 2025 amounted to $36,000 and $29,000, respectively and is reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

36000

29000

Share-Based Compensation We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

Advertising Costs Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $12,000 and $16,000 for the years ended June 30, 2026 and 2025 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

12000

16000

Research and Development Costs Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees related to the Company’s cold plasma technology, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2026 and 2025 amounted to $11,000 and $95,000, respectively.

11000

95000

Warranty Policy The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2026 and 2025.

Net Loss Per Share The Company’s computation of net loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. There were no adjustments to net loss required for purposes of computing diluted earnings per share. At June 30, 2026 and 2025 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive as the exercise price of these warrants were greater than the stock price of the Company common stock. <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2tVDMl7Bn1e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of anti-dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLBDTQ6EXzJl" style="width: 13%; text-align: right" title="Antidilutive shares">31,571,784</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk3u5emk06Fd" style="width: 13%; text-align: right" title="Antidilutive shares">49,041,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zPfP2rUkiHb9" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">1,295,639</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zRuectThUzZi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630_zWoH5rANeOHc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">32,867,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240701__20250630_zSq2RR3ASHj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">49,041,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2tVDMl7Bn1e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of anti-dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLBDTQ6EXzJl" style="width: 13%; text-align: right" title="Antidilutive shares">31,571,784</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk3u5emk06Fd" style="width: 13%; text-align: right" title="Antidilutive shares">49,041,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zPfP2rUkiHb9" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">1,295,639</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zRuectThUzZi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260630_zWoH5rANeOHc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">32,867,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240701__20250630_zSq2RR3ASHj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">49,041,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

31571784

49041323

1295639

32867423

49041323

Concentrations During the year ended June 30, 2026 we recorded <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetMember_z9wRZ89lJ97c" title="Concentration risk percentage">100% of our revenue from one rental customer and for the year ended June 30, 2025 we recorded <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetMember_zMlqkjmmxg8h" title="Concentration risk percentage">98% of our revenue from Desmet Ballestra (Desmet) (see Note 2). As of June 30, 2026, two vendors accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zA0lb0D0sRl7" title="Concentration risk, percentage">18% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z4NEyec7TjTa" title="Concentration risk, percentage">15% of the Company’s accounts payable. As of June 30, 2025, two vendors accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zqTT6qNdn6Jj" title="Concentration risk, percentage">18% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z8LQm1Mucpvg" title="Concentration risk, percentage">7% of the Company’s accounts payable. At June 30, 2026, we had no receivables. As of June 30, 2025, one customer accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zk4CX9NCSeU1" title="Concentration risk, percentage">100% of the Company’s accounts receivable.

0.98

0.18

0.15

0.18

0.07

Segments The Company operates in one segment for the development and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s Chief Operating Decision Maker (CODM) has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base, single sales team, marketing department, customer service department, operations department, finance and accounting department to support its operations and similarities in economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in Note 12.

Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Reclassification of prior year presentation As of June 30, 2026, the Company reclassified $15,000 of accrued interest, which was previously included in accounts payable and accrued expenses at June 30, 2025, to note payable – non-current. In addition, $3,000 of accrued interest that was previously included in accounts payable and accrued expenses was reclassified to accrued interest payable in the current-year presentation. These reclassifications were made to conform the prior-year amounts to the current-year presentation and had no effect on total liabilities, net loss, or stockholders’ equity (deficit).

15000

3000

Note 2 – Contracts with Desmet Ballestra Research and Development, Marketing and Technology License Agreements (“TLA”) In October 2021, the Company signed a three-year global Research and Development, Marketing and Technology License Agreement (“TLA”) with Desmet Ballestra (“Desmet”) for the sale and licensing of the Company’s nano reactors. This agreement was a continuation of the similar TLA agreements the Company signed with Desmet in fiscals 2012, 2016 and 2018. On February 15, 2024, Desmet and the Company terminated the October 2021 TLA agreement and entered into a new three-year Technology License Agreement (“February 2024 TLA”). The February 2024 TLA provides for a worldwide limited exclusive license to market, sell, supply and assistance to customers of Nano reactor systems and nano reactor devices for the treatment of certain oil and fats, oleochemicals, biodiesels, fatty acids and fatty alcohols. The February 2024 TLA may be terminated by Desmet on March 15 each year on at least one month’s written notice if the licensee and its affiliates failed to sell a minimum of 6 nano reactor systems during the preceding 12 month period. As part of the February 2024 TLA, Desmet also agreed to provide advances of $25,000 per month, subject to limitations. The advances will then be applied as payment against future sales of reactors to Desmet. On October 9, 2024, the Company executed a Patent Assignment and License Back Agreement with Desmet with regards to the patents and intellectual property used in the production of reactors sold to Desmet. This agreement superseded certain terms of the February 2024 TLA, including, the termination of $25,000 monthly advances the Company used to receive from Desmet. During the year ended June 30, 2026 and 2025, pursuant to these TLA agreements, the Company recognized revenues from sale of Nano Reactors to Desmet totaling $<span id="xdx_90A_eus-gaap--Revenues_c20250701__20260630__srt--CounterpartyNameAxis__custom--DesmetBallestraMember__srt--ProductOrServiceAxis__custom--NanoReactorsMember__us-gaap--TypeOfArrangementAxis__custom--TLAAgreementMember_zjie4COxj0n9">0 and $<span id="xdx_90B_eus-gaap--Revenues_c20240701__20250630__srt--CounterpartyNameAxis__custom--DesmetBallestraMember__srt--ProductOrServiceAxis__custom--NanoReactorsMember__us-gaap--TypeOfArrangementAxis__custom--TLAAgreementMember_zvMO7mzDKyJ8">198,000, respectively. Patent Assignment and License Back Agreement On October 9, 2024, the Company entered into a patent assignment and license back agreement with Desmet, whereby the Company assigned certain of its U.S. and non-U.S. patents, technical information and related intellectual property (the “Assigned Patents”) that for several years have been licensed to Desmet, on a global basis, for its use in vegetable oil, fats and oleo applications, effectively terminating the February 2024 TLA Agreement. The Company also assigned to Desmet, ownership of two U.S. trademark registrations that it holds for its Nano Neutralization® and Nano Reactor® marks, respectively (the “Assigned Marks”). The consideration for the assignment of the patents amounted to $<span id="xdx_900_eus-gaap--GainLossOnDispositionOfIntangibleAssets_c20241008__20241009__srt--CounterpartyNameAxis__custom--DesmetMember__us-gaap--TypeOfArrangementAxis__custom--PatentAssignmentAndLicenseBackAgreementMember_zDjKwZrDADBa" title="Gain on disposition of patent">880,000, which was collected in full. The Company has also agreed to provide to Desmet any consultation, technical assistance and support services that Desmet may reasonably request in; (a) installing, operating or troubleshooting for any Nano Reactor® Device; (b) testing, startup or maintenance of any Nano Reactor® Device or any problems associated therewith; and (c) providing training to representatives, contractors or employees of Desmet or any Site User, to be charged at a rate of $1,000 per day, plus reimbursement of reasonable expenses. Pursuant to the patent assignment and license back agreement, the Company reserved for itself, and received a Grant Back License (“Reserved Grant Back License”) of a worldwide, exclusive, transferable and royalty-free license and right to practice and use the Assigned Patents and associated technical information in businesses, activities, projects, uses and applications in the field of; (i) water and wastewater processing, recovery, recycling and purification (including oilfield wastewater) and; (ii) manufacture, distillation, brewing, enhancements, sale and marketing of alcoholic beverages, together the Licensed Fields (the “Licensed Fields”). Under the Reserved Grant Back License retained and received, the Company will have a worldwide, exclusive, transferable and royalty-free license and right to design, build, use, export, improve, sell and market Nano Reactor® devices and Nano Reactor® devices and systems (and products) that incorporate or utilize Nano Reactor® devices, in each case within the Licensed Fields, and to continue to use the Nano Reactor® trademark in connection with its business, systems and products within the Licensed Fields. The Company has expensed costs associated with these patents in prior years and had no carrying value upon closing of this transaction. The Company followed the guidance of ASC 610, Other Income, to account for this transaction. As a result, during the year ended June 30, 2025, the Company recognized the entire $<span id="xdx_90F_eus-gaap--GainLossOnDispositionOfIntangibleAssets_c20240701__20250630__srt--CounterpartyNameAxis__custom--DesmetMember__us-gaap--TypeOfArrangementAxis__custom--PatentAssignmentAndLicenseBackAgreementMember_zanOOtz6lMi2" title="Gain on disposition of patent">880,000 as Gain on Patent Assignment in the accompanying Consolidated Statement of Operations.

198000

880000

Note 3 – Commitments and Contingencies Royalty Agreements On July 1, 2008, the Company’s wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2026. On April 30, 2008 (as amended November 22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of June 30, 2026, and 2025 no patents have been granted in which this person is the legally named inventor. Other From time to time the Company may be named in claims arising in the ordinary course of business. Currently, there are no such legal proceedings that are pending against the Company or that involve the Company that, in the opinion of management, could reasonably be expected to have a material adverse effect on the Company’s business or financial condition.

Note 4 – Bridge Note Payable <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfBridgeNotePayableTableTextBlock_zGo6D4EURuv2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Bridge Note Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Schedule of bridge note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zw52Vk61GEf7" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20250630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_z4TWCB04HYtj" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Principal </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_zOigebv0Ua4h" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 1pt">Bridge note payable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">111,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_znBDJbcOatw6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Discount on issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_z8n1EK71iReh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_z9eq7VFKXICb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShortTermBorrowings_iI_d0_zsGCn3XnTmqf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Bridge note payable, Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">103,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> On May 11, 2026, the Company entered into a bridge note with a lender for $111,000 for net proceeds of $100,000, after direct expenses of $11,000, which was recorded as a debt discount to be amortized over the term of the note. The note matures on March 11, 2027, ten months after issuance date. The Bridge note bears interest at 24% of the value of the bridge note ($27,000) regardless of repayment date, resulting in an effective interest rate of 30.16% based on the repayment schedule. Additional tranches of funding are available up to a total of $500,000 during the <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20260510__20260511__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zndolxiocwj6" title="Line of credit expiration period">12 months ending May 11, 2027. The bridge note is repayable in five instalments, $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20261029__20261030__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1YCvU6t0Nq3" title="Debt periodic payment">70,000 on October 30, 2026, $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20261129__20261130__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM7mKwKiW5a9"><span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20261229__20261230__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhs8UgXNBe"><span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_c20270129__20270130__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMnpJliJh4U6"><span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20270227__20270228__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9e4prmgBkP8">17,000 on each of November 30, 2026, December 30, 2026, January 30, 2027 and February 28, 2027. In the event of default, the principal balance of the note will be increased by 150%, and after the expiry of 180 days, the note may be converted into shares of common stock at the option of the lender, at a conversion price of 65% of the lowest closing bid price of the Company’s common stock during the ten day trading period prior to conversion, with conversion limited to 4.99% of the total issued and outstanding common stock at the time of conversion. The note may be prepaid up to 180 days from date of issuance with prepayment discounts ranging from 95% to 98% of the total amount outstanding, including the interest of $27,000.

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfBridgeNotePayableTableTextBlock_zGo6D4EURuv2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Bridge Note Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Schedule of bridge note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zw52Vk61GEf7" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20250630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_z4TWCB04HYtj" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Principal </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_zOigebv0Ua4h" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 1pt">Bridge note payable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">111,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_znBDJbcOatw6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Discount on issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_z8n1EK71iReh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_z9eq7VFKXICb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShortTermBorrowings_iI_d0_zsGCn3XnTmqf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Bridge note payable, Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">103,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

111000

11000

-0

3000

8000

-0

103000

111000

100000

11000

2027-03-11

0.24

27000

0.3016

500000

P12M

2027-05-11

70000

17000

27000

Note 5 – Promissory Notes Payable – Related Party <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfNotePayableRelatedPartyTableTextBlock_zvoAjl0BX8o2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Promissory Notes payable - Related party (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of note payable- related party</td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20260630_zpHUe5E1YcR8" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250630_zJk3If2DZS55" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Principal </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--NotesPayableRelatedParty_iI_d0_zwJnPHZKVMK1" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Promissory note payable - related party</td><td style="width: 2%; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; font-weight: bold; text-align: right">115,000</td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Between January 9, 2026 and May 4, 2026, the Company entered into five promissory note agreements with an entity associated with the Company’s CEO, wherein the entity advanced the Company an aggregate of $115,000 to fund operations. The promissory notes are unsecured, bear interest at 8% per annum and mature six months after advance. These promissory notes payable were subsequently amended to extend the respective maturity dates by another six months with no changes to the other original terms of the agreement or compensation paid to the noteholder. <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfNotePayableRelatedPartyTableTextBlock_zvoAjl0BX8o2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Promissory Notes payable - Related party (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of note payable- related party</td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20260630_zpHUe5E1YcR8" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250630_zJk3If2DZS55" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Principal </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--NotesPayableRelatedParty_iI_d0_zwJnPHZKVMK1" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Promissory note payable - related party</td><td style="width: 2%; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; font-weight: bold; text-align: right">115,000</td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 115000 0

115000

0.08

Note 6– Convertible Notes Payable <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zNrxNNRpOmZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Note (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Schedule of convertible notes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zCelwqbT4pp2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20250630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zTb9da2JfQKb" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Principal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_d0_zzJAZKW5vPgk" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 1pt">Convertible note payable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_z59ryml3M50g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Discount on issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(38,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_z49BSnGZY8oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_zbYkC6qvOWT7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_d0_zaPixNuOPyMg" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In December 2025 and January 2026, Xyra Corp., the Company’s wholly owned subsidiary issued three one-year convertible notes, amounting to $60,000, with maturity dates from <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20250701__20260630__us-gaap--LongtermDebtTypeAxis__custom--XyraCorpConvertibleNotesMember_zykTtmqOd3fh" title="Debt maturity date, start range">December 5, 2026 to <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20250701__20260630__us-gaap--LongtermDebtTypeAxis__custom--XyraCorpConvertibleNotesMember_z7TuztXVXOrf" title="Debt maturity date, end range">January 30, 2027, with a stated annual interest rate of 8%. The Company, prior to the maturity date, has the option to extend the maturity date of the note by an additional six months. The note may be prepaid at any time without penalty. The holder has an option to convert the principal of the convertible note into Xyra common stock for a period of six months once notified by the Company, in writing, of a public listing on any recognized U.S. national or regional stock exchange or on any of the markets operated by the OTC Markets Group. The conversion price will be 50% of the 5-day average closing price immediately prior to conversion. Xyra, at its sole discretion may allow the conversion of unpaid interest into Xyra common stock for the same period allowed for the conversion of the principal. Should Xyra not achieve a public offering by December 5, 2026, the holder has the option to convert the principal outstanding into common shares of the Company for a period of six months from December 5, 2026. The conversion price will be the greater of 80% of $0.06 or the current CTI market price. The market price will be determined as the weighted average of the high and low trading prices of the Company stock over a 5-day period. The Company at its sole discretion may allow the conversion of interest at any time after the maturity date and during any extended period exercised by Xyra. The Company analyzed the conversion options for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined that the conversion options should be accounted as a derivative liability since it does not have an explicit limit to the number of shares to be delivered upon settlement of the conversion option (see Note 7). The cumulative fair value of the derivative liability upon issuance of the convertible notes payable at issuance date amounted to $38,000, and accounted as a debt discount, which is being amortized to interest expense over the term of the corresponding notes payable.

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zNrxNNRpOmZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Note (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Schedule of convertible notes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zCelwqbT4pp2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20250630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zTb9da2JfQKb" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Principal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_d0_zzJAZKW5vPgk" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 1pt">Convertible note payable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_z59ryml3M50g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Discount on issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(38,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_z49BSnGZY8oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_zbYkC6qvOWT7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_d0_zaPixNuOPyMg" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

60000

38000

-0

12000

26000

-0

34000

60000

2026-12-05

2027-01-30

0.08

38000

Note 7 – Derivative Liability In December 2025 and January 2026, the Company issued convertible notes payable whose conversion options are being accounted as a derivative liability pursuant to ASC 815, Derivatives and Hedging (see Note 6). The derivative liability is remeasured to fair value at each reporting period, and the change in the fair value is recognized in earnings in the accompanying statements of operations. The Company estimated the fair value of the conversion option derivative liability using a variable option pricing model. The following table provides a roll-forward of the derivative liability measured at fair value on a recurring basis using unobservable level 3 inputs for the period ended June 30, 2026, as follows: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zriWSYsoTD8k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details - rollforward of derivative liability)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of rollforward of derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value of Derivative Liability</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%">Fair value of derivative liability at issuance in December 2025 and January 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20251201__20260630_ztRkEFEVlp4b" title="Fair value of derivative liability at issuance in December 2025 and January 2026">38,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20251201__20260630_zv9brkRgsEK4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(24,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value of derivative liability at June 30, 2026</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20251201__20260630_zoIF5GD0k2f7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value of derivative liability at June 30, 2026">14,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> The following are the average inputs used by the Company in the valuation of the derivative liability: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zUWvT1ai6Gx2" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td>Schedule of assumptions used</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 82%">Stock price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 15%"><span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zAiV0QE2MHnd" title="Assumption used">0.03 to 0.08</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zcWf7L2KpKc3" title="Assumption used">3.48% to 4.01%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpSjaRzy9P35" title="Assumption used">174.5% to 236.5%</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expected life in months</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_ztf24AfxrwUb" title="Assumption used">12</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Number of common stock issuable</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputNumberOfSharesIssuableMember_zUz0PYaqUgsk" title="Assumption used">1,206,140 to 1,295,639</td> <td> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zriWSYsoTD8k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details - rollforward of derivative liability)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of rollforward of derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value of Derivative Liability</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%">Fair value of derivative liability at issuance in December 2025 and January 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20251201__20260630_ztRkEFEVlp4b" title="Fair value of derivative liability at issuance in December 2025 and January 2026">38,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20251201__20260630_zv9brkRgsEK4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(24,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value of derivative liability at June 30, 2026</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20251201__20260630_zoIF5GD0k2f7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value of derivative liability at June 30, 2026">14,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

38000

-24000

14000

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zUWvT1ai6Gx2" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td>Schedule of assumptions used</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 82%">Stock price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 15%"><span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zAiV0QE2MHnd" title="Assumption used">0.03 to 0.08</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zcWf7L2KpKc3" title="Assumption used">3.48% to 4.01%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpSjaRzy9P35" title="Assumption used">174.5% to 236.5%</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expected life in months</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_ztf24AfxrwUb" title="Assumption used">12</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Number of common stock issuable</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250701__20260630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputNumberOfSharesIssuableMember_zUz0PYaqUgsk" title="Assumption used">1,206,140 to 1,295,639</td> <td> </td></tr> </table>

0.03 to 0.08

3.48% to 4.01%

174.5% to 236.5%

1,206,140 to 1,295,639

Note 8 – Note Payable <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zSnLhd8Z0Cvd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Note Payable (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of notes payable</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Note payable - EIDL</td><td style="width: 2%; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20260630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_z3iV5ZNwzjVi" style="border-bottom: Black 2.5pt double; width: 13%; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20250630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_zW7RVsjC0aQa" style="border-bottom: Black 2.5pt double; width: 13%; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> In July 2020, the Company received a loan of $150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of 3.75% per annum and secured by all tangible and intangible property of the Company. Pursuant to the Company’s agreement with the SBA in the prior year that cured prior payment defaults and past due balances, monthly installment payments are first being applied to accrued and unpaid interest. As of June 30, 2026 and June 30, 2025, the outstanding balance of the note payable was $150,000 and $150,000, respectively. The expected future principal payments of the note payable at June 30, 2026, is as follows: <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zFRtlgBcmLe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Note Payable (Details - Minimum future payments)"> <tr style="vertical-align: bottom"> <td>Schedule of future minimum payments on note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260630_zS4mKV9R1Ine" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold">Year Ending</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_d0_z1EaqbSYKdZg" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>June 30, 2027</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_d0_zmWxWfZvDvHh" style="vertical-align: bottom; background-color: White"> <td>June 30, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_d0_zqi7DhII5Tej" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>June 30, 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_zF0kcE1D9j94" style="vertical-align: bottom; background-color: White"> <td style="width: 83%">June 30, 2030</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">3,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_iI_zhXOioRclZV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">June 30, 2031 and thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">147,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebt_iI_zoKMyIXHNlvh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zSnLhd8Z0Cvd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Note Payable (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of notes payable</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Note payable - EIDL</td><td style="width: 2%; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20260630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_z3iV5ZNwzjVi" style="border-bottom: Black 2.5pt double; width: 13%; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20250630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_zW7RVsjC0aQa" style="border-bottom: Black 2.5pt double; width: 13%; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

150000

0.0375

150000

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zFRtlgBcmLe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Note Payable (Details - Minimum future payments)"> <tr style="vertical-align: bottom"> <td>Schedule of future minimum payments on note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260630_zS4mKV9R1Ine" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold">Year Ending</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_d0_z1EaqbSYKdZg" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>June 30, 2027</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_d0_zmWxWfZvDvHh" style="vertical-align: bottom; background-color: White"> <td>June 30, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_d0_zqi7DhII5Tej" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>June 30, 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_zF0kcE1D9j94" style="vertical-align: bottom; background-color: White"> <td style="width: 83%">June 30, 2030</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">3,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_iI_zhXOioRclZV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">June 30, 2031 and thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">147,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebt_iI_zoKMyIXHNlvh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

3000

147000

150000

Note 9 - Stockholders’ Deficit Preferred Stock On March 17, 2009, the Company filed an Amended and Restated Articles of Incorporation and created two new series of preferred stock, the first of which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. Each share of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2026, and 2025, there are no shares of Series A or Series B Preferred Stock issued and outstanding. Common Stock Year Ending June 30, 2026 During the year ended June 30, 2026, the Company conducted an offering and issued 8,269,399 shares of its common stock to accredited investors in exchange for cash of $248,000. As part of the offering, the Company also granted warrants to these investors to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxCI6xcB5Mbh" title="Granted shares">8,269,399 shares of common stock. The warrants are fully vested, exercisable at $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxVHqOCaY45a" title="Vested, per share">0.05 and $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageGrantDateFairValue_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcDENYFIctZb" title="Exercisable price">0.06 per share and will expire in five years. In addition, certain investors also agreed to forfeit or retire an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB9tYsJ2rzQe" title="Forfeit or retire shares">5,769,400 warrants granted to them in the prior year, which had an exercise price of $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zU96CUupNYm" title="Exercise price">0.09 per share. During the year ended June 30, 2026, the Company issued an aggregate of 8,300,000 shares of common stock to various consultants for services rendered. The common stock issued was valued at fair market value on the grant date at $394,000. Year Ending June 30, 2025 In February 2025, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20250201__20250228__us-gaap--RelatedPartyTransactionAxis__custom--SettlementOfAccruedPayrollMember_zTSFyN53KVs1" title="Stock issued for compensation, shares">4,666,600 shares of common stock with a fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20250201__20250228__us-gaap--RelatedPartyTransactionAxis__custom--SettlementOfAccruedPayrollMember_zy8GiNBJHjI3" title="Stock issued for compensation, value">90,000 to settle accrued payroll and payroll taxes – related party (see Note 11). On June 10, 2025, the Company issued 200,000 shares of common stock with a fair value of $6,000 for consulting services. Stock Options The Company has not adopted a formal stock option plan and does not have any stock options issued and outstanding as of and during the years ended June 30, 2026 and 2025. Warrants Year ended June 30, 2026 On November 25, 2025, certain warrant holders, including the Company’s CEO exercised warrants for an aggregate of <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20251124__20251125__srt--CounterpartyNameAxis__custom--CertainWarrantHoldersMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zPigjVOuzNVb" title="Stock converted, shares converted">13,700,000 shares of common stock on a cashless basis in accordance with terms of the warrant agreements. As a result, the Company issued <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20251124__20251125__srt--CounterpartyNameAxis__custom--CertainWarrantHoldersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_z6qsX6IPtOg" title="Stock converted, shares issued">11,495,000 shares of common stock. Year ended June 30, 2025 In November 2024 and February 2025, the Company granted 5 year warrants exercisable for 15,200,000 shares of common stock at exercise prices ranging from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241130__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zwAfbdI0nm15" title="Warrants exercise price"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zAwyoRSKkhN9" title="Warrants exercise price">0.013 to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241130__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpB4CvRbuvr6" title="Warrants exercise price"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdFkxYRuRI4" title="Warrants exercise price">0.017 per share to employees and certain consultants for services rendered. The estimated fair value amounted to $195,000 and was derived using the Black Scholes Option Pricing Model using the following inputs (i) stock price at the date of grant ranging from $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_zHghbSCzDiDg" title="Share price"><span id="xdx_907_eus-gaap--SharePrice_iI_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_zcY7ecrcQgi3" title="Share price">0.010 to $<span id="xdx_903_eus-gaap--SharePrice_iI_c20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MaximumMember_zDcpHH4ryf3i" title="Share price"><span id="xdx_907_eus-gaap--SharePrice_iI_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MaximumMember_zI5WM9ZBNMwb" title="Share price">0.020; (ii) risk free interest rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241101__20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_zd4amZzUdub7" title="Risk free rate of return"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_ztOk25v9bo93" title="Risk free rate of return">4.24% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241101__20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MaximumMember_z9oqnCxd5yJ8" title="Risk free rate of return"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MaximumMember_z2LG0pTyqYp7" title="Risk free rate of return">4.37% based on rates established by the Federal Reserve Bank; (iii) expected volatility <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241101__20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_zTLVrvK7CVRf" title="Volatility rate"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_zHrCAnBwVpPk" title="Volatility rate">283% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241101__20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MaximumMember_zfeUZsfPnyf3" title="Volatility rate"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MaximumMember_zz5cbQQmnup2" title="Volatility rate">290% based on historical volatility of the Company’s common stock commensurate with the expected life of the warrants; (iv) expected life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241101__20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember_zYWEeiStfMl8" title="Expected term"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember_zw1NNC1qoZK9" title="Expected term">5 years based on the contractual life; and (v) dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20241101__20241130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_z676f7CjHCbb" title="Dividend yield percentage"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BlackScholesOptionMember__srt--RangeAxis__srt--MinimumMember_zW0660Nji5g2" title="Dividend yield percentage">0% based on no dividends paid or expected to be paid. In February 2025, the Company issued warrants to purchase <span id="xdx_905_ecustom--WarrantsIssuedShares_c20250201__20250228__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember__us-gaap--TransactionTypeAxis__custom--SettlementOfAccruedPayrollMember_zY1VHcK6qig5" title="Warrants issued, shares">5,000,000 shares of common stock with an estimated fair value of $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c20250201__20250228__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember__us-gaap--TransactionTypeAxis__custom--SettlementOfAccruedPayrollMember_z5OjbMODOg3h" title="Fair value of warrants issued">100,000 to settle accrued payroll – related party (see Note 11). A summary of the Company’s warrant activity and related information from as of June 30, 2026 and 2025 is as follows. <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zcAA3UlTbxEc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrant activity)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Schedule of warrant activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Outstanding at June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqltAoC6kDF9" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">28,841,323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRHjLU5hDx1j" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price, beginning balance">0.080</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpnjdhMnmJ7h" title="Weighted average remaining contractual life">2.61</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlyExP8Z6gj" style="text-align: right" title="Warrants granted">20,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdaf393Hk8Cg" style="text-align: right" title="Warrants granted, weighted average exercise price">0.015</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhzRLZELhpul" title="Weighted average remaining contractual life, granted">4.76</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ulQNXzNcCc" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziW0nnxOHfJa" style="text-align: right" title="Warrants exercised, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVK6Qqj4WSw8" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkaqCWigayo2" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, weighted average exercise price">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Outstanding at June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwh5Hw8waTHi" style="text-align: right" title="Warrants outstanding, beginning balance">49,041,323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNSfRLbq5wv2" style="text-align: right" title="Warrants outstanding, weighted average exercise price, beginning balance">0.053</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWhhOLZqxnGk" title="Weighted average remaining contractual life">2.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkcajIojUlnb" style="text-align: right" title="Warrants granted">8,269,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKQENY9eXVad" style="text-align: right" title="Warrants granted, weighted average exercise price">0.055</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsB1jeqxC1bd" title="Weighted average remaining contractual life, granted">4.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjT5gUmuQEVd" style="text-align: right" title="Warrants exercised">(13,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFn9ufjMc6Wh" style="text-align: right" title="Warrants exercised, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN3eI0PiKD23" style="text-align: right" title="Warrants exercised">(5,769,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4GaJM79J4Ab" style="text-align: right" title="Warrants exercised, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYG30nQCMQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(6,269,538</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9jI3VhURLfd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, weighted average exercise price">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDoRcAyhdsCl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">31,571,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyMD0tP6c02h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, weighted average exercise price, ending balance">0.056</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDTk9PtifWO2" title="Weighted average remaining contractual life">2.47</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of June 30, 2026, the intrinsic value of these stock purchase warrants amounted to $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7OleJ5OKQi3" title="Intrinsic value of warrants">61,000. The following table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2026. <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zkhM6OOSoG9c" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)"> <tr style="vertical-align: bottom"> <td colspan="2">Schedule of warrants outstanding and exercisable</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Warrants Outstanding</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Warrants Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">of Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">of Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.013</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zQYScDr82xnj" style="width: 14%; text-align: right" title="Warrants outstanding">2,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_ziUMfAcXLpUj" title="Weighted average remaining life, warrants outstanding">3.39</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zOaVqKxlKN4e" style="width: 14%; text-align: right" title="Weighted average exercise price">0.013</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zrkGE4A1ebNd" style="width: 14%; text-align: right" title="Warrants exercisable">2,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_z9D9nEzFdTqd" title="Weighted average remaining life, warrants exercisable">3.39</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: #EEEEEE">$</td> <td style="text-align: right">0.017</td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_z9PK9OzIMOf6" style="text-align: right" title="Warrants outstanding">4,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zBEEDarLTdBl" title="Weighted average remaining life, warrants outstanding">3.67</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_z8Sqh01ltAI" style="text-align: right" title="Weighted average exercise price">0.017</td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zUFefv6kbXg4" style="text-align: right" title="Warrants exercisable">4,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_z8WjLYn2J0jb" title="Weighted average remaining life, warrants exercisable">3.67</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">$</td> <td style="background-color: #EEEEEE; text-align: right">0.030</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_z1SoYmgwPxxj" style="background-color: #EEEEEE; text-align: right" title="Warrants outstanding">5,000,000</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zO4avm7Ipgnj" title="Weighted average remaining life, warrants outstanding">3.51</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE">$</td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zxze85ofnKu" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price">0.030</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_ztjm23Xfi1qi" style="background-color: #EEEEEE; text-align: right" title="Warrants exercisable">5,000,000</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zoZ9fCVgdLEi" title="Weighted average remaining life, warrants exercisable">3.51</td> <td style="background-color: #EEEEEE"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.045</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zkUKc4q4uNJg" style="text-align: right" title="Warrants outstanding">2,499,999</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zPlzLgvlDVul" title="Weighted average remaining life, warrants outstanding">4.85</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zSHkg97Vft1b" style="text-align: right" title="Weighted average exercise price">0.045</td> <td> </td> <td> </td> <td> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zO2PqEKbqDji" style="text-align: right" title="Warrants exercisable">2,499,999</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zHJ3OeLKn2ni" title="Weighted average remaining life, warrants exercisable">4.85</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">$</td> <td style="background-color: #EEEEEE; text-align: right">0.060</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_zi96g4VRj7Fd" style="background-color: #EEEEEE; text-align: right" title="Warrants outstanding">5,769,400</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_zdz0LREYlkpj" title="Weighted average remaining life, warrants outstanding">4.28</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE">$</td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_z0dU0yTcJ6Kd" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price">0.060</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_zSxcVtdTz0l1" style="background-color: #EEEEEE; text-align: right" title="Warrants exercisable">5,769,400</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_z5uLKB6v6Yo3" title="Weighted average remaining life, warrants exercisable">4.28</td> <td style="background-color: #EEEEEE"> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: #EEEEEE">$</td> <td style="text-align: right">0.090</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zeoFzV8XxZfk" style="border-bottom: black 1pt solid; text-align: right" title="Warrants outstanding">11,802,385</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zHE4uyBtIjld" title="Weighted average remaining life, warrants outstanding">0.03</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zhJzan9dw4I4" style="text-align: right" title="Weighted average exercise price">0.090</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zhpjH6Zc522h" style="border-bottom: black 1pt solid; text-align: right" title="Warrants exercisable">11,802,385</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_z6AtUpFxNuHf" title="Weighted average remaining life, warrants exercisable">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zOzuZs7tsFKk" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding">31,571,784</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zTP66XcEHd99" title="Weighted average remaining life, warrants outstanding">2.47</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zBwzwith8Mqk" style="text-align: right" title="Weighted average exercise price">0.056</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zrOuHUfl4Nl9" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable">31,571,784</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zB7UR8Okwaue" title="Weighted average remaining life, warrants exercisable">2.47</td> <td> </td></tr> </table>

1000000000

10000000

5000000

0.001

8269399

248000

8269399

0.05

0.06

5769400

0.09

8300000

394000

4666600

90000

200000

6000

13700000

11495000

P5Y

15200000

0.013

0.017

195000

0.010

0.020

0.0424

0.0437

2.83

2.90

P5Y

5000000

100000

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zcAA3UlTbxEc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrant activity)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Schedule of warrant activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Outstanding at June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqltAoC6kDF9" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">28,841,323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRHjLU5hDx1j" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price, beginning balance">0.080</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpnjdhMnmJ7h" title="Weighted average remaining contractual life">2.61</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlyExP8Z6gj" style="text-align: right" title="Warrants granted">20,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdaf393Hk8Cg" style="text-align: right" title="Warrants granted, weighted average exercise price">0.015</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhzRLZELhpul" title="Weighted average remaining contractual life, granted">4.76</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4ulQNXzNcCc" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziW0nnxOHfJa" style="text-align: right" title="Warrants exercised, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVK6Qqj4WSw8" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkaqCWigayo2" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, weighted average exercise price">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Outstanding at June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwh5Hw8waTHi" style="text-align: right" title="Warrants outstanding, beginning balance">49,041,323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNSfRLbq5wv2" style="text-align: right" title="Warrants outstanding, weighted average exercise price, beginning balance">0.053</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWhhOLZqxnGk" title="Weighted average remaining contractual life">2.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkcajIojUlnb" style="text-align: right" title="Warrants granted">8,269,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKQENY9eXVad" style="text-align: right" title="Warrants granted, weighted average exercise price">0.055</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsB1jeqxC1bd" title="Weighted average remaining contractual life, granted">4.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjT5gUmuQEVd" style="text-align: right" title="Warrants exercised">(13,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFn9ufjMc6Wh" style="text-align: right" title="Warrants exercised, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN3eI0PiKD23" style="text-align: right" title="Warrants exercised">(5,769,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4GaJM79J4Ab" style="text-align: right" title="Warrants exercised, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYG30nQCMQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(6,269,538</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9jI3VhURLfd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, weighted average exercise price">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDoRcAyhdsCl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">31,571,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyMD0tP6c02h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, weighted average exercise price, ending balance">0.056</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDTk9PtifWO2" title="Weighted average remaining contractual life">2.47</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

28841323

0.080

P2Y7M9D

20200000

0.015

P4Y9M3D

-0

49041323

0.053

P2Y9M21D

8269399

0.055

P4Y5M12D

13700000

5769400

6269538

31571784

0.056

P2Y5M19D

61000

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zkhM6OOSoG9c" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)"> <tr style="vertical-align: bottom"> <td colspan="2">Schedule of warrants outstanding and exercisable</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Warrants Outstanding</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Warrants Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">of Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">of Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.013</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zQYScDr82xnj" style="width: 14%; text-align: right" title="Warrants outstanding">2,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_ziUMfAcXLpUj" title="Weighted average remaining life, warrants outstanding">3.39</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zOaVqKxlKN4e" style="width: 14%; text-align: right" title="Weighted average exercise price">0.013</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zrkGE4A1ebNd" style="width: 14%; text-align: right" title="Warrants exercisable">2,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_z9D9nEzFdTqd" title="Weighted average remaining life, warrants exercisable">3.39</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: #EEEEEE">$</td> <td style="text-align: right">0.017</td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_z9PK9OzIMOf6" style="text-align: right" title="Warrants outstanding">4,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zBEEDarLTdBl" title="Weighted average remaining life, warrants outstanding">3.67</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_z8Sqh01ltAI" style="text-align: right" title="Weighted average exercise price">0.017</td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zUFefv6kbXg4" style="text-align: right" title="Warrants exercisable">4,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_z8WjLYn2J0jb" title="Weighted average remaining life, warrants exercisable">3.67</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">$</td> <td style="background-color: #EEEEEE; text-align: right">0.030</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_z1SoYmgwPxxj" style="background-color: #EEEEEE; text-align: right" title="Warrants outstanding">5,000,000</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zO4avm7Ipgnj" title="Weighted average remaining life, warrants outstanding">3.51</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE">$</td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zxze85ofnKu" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price">0.030</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_ztjm23Xfi1qi" style="background-color: #EEEEEE; text-align: right" title="Warrants exercisable">5,000,000</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zoZ9fCVgdLEi" title="Weighted average remaining life, warrants exercisable">3.51</td> <td style="background-color: #EEEEEE"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.045</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zkUKc4q4uNJg" style="text-align: right" title="Warrants outstanding">2,499,999</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zPlzLgvlDVul" title="Weighted average remaining life, warrants outstanding">4.85</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zSHkg97Vft1b" style="text-align: right" title="Weighted average exercise price">0.045</td> <td> </td> <td> </td> <td> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zO2PqEKbqDji" style="text-align: right" title="Warrants exercisable">2,499,999</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zHJ3OeLKn2ni" title="Weighted average remaining life, warrants exercisable">4.85</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">$</td> <td style="background-color: #EEEEEE; text-align: right">0.060</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_zi96g4VRj7Fd" style="background-color: #EEEEEE; text-align: right" title="Warrants outstanding">5,769,400</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_zdz0LREYlkpj" title="Weighted average remaining life, warrants outstanding">4.28</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE">$</td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_z0dU0yTcJ6Kd" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price">0.060</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_zSxcVtdTz0l1" style="background-color: #EEEEEE; text-align: right" title="Warrants exercisable">5,769,400</td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE"> </td> <td style="background-color: #EEEEEE; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice5Member_z5uLKB6v6Yo3" title="Weighted average remaining life, warrants exercisable">4.28</td> <td style="background-color: #EEEEEE"> </td></tr> <tr style="vertical-align: bottom"> <td style="background-color: #EEEEEE">$</td> <td style="text-align: right">0.090</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zeoFzV8XxZfk" style="border-bottom: black 1pt solid; text-align: right" title="Warrants outstanding">11,802,385</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zHE4uyBtIjld" title="Weighted average remaining life, warrants outstanding">0.03</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zhJzan9dw4I4" style="text-align: right" title="Weighted average exercise price">0.090</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_zhpjH6Zc522h" style="border-bottom: black 1pt solid; text-align: right" title="Warrants exercisable">11,802,385</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice6Member_z6AtUpFxNuHf" title="Weighted average remaining life, warrants exercisable">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zOzuZs7tsFKk" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding">31,571,784</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zTP66XcEHd99" title="Weighted average remaining life, warrants outstanding">2.47</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zBwzwith8Mqk" style="text-align: right" title="Weighted average exercise price">0.056</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zrOuHUfl4Nl9" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable">31,571,784</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zB7UR8Okwaue" title="Weighted average remaining life, warrants exercisable">2.47</td> <td> </td></tr> </table>

2000000

P3Y4M20D

0.013

2000000 P3Y4M20D

4500000

P3Y8M1D

0.017

4500000 P3Y8M1D

5000000

P3Y6M3D

0.030

5000000 P3Y6M3D

2499999

P4Y10M6D

0.045

2499999 P4Y10M6D

5769400

P4Y3M10D

0.060

5769400 P4Y3M10D

11802385

P0Y10D

0.090

11802385 P0Y10D

31571784

P2Y5M19D

0.056

31571784 P2Y5M19D

Note 10 - Income Taxes For the year ended June 30, 2026 the Company recorded no provision for income taxes due to the Company’s taxable net loss position. For the year ended June 30, 2025 the Company recorded no provision for income taxes due to the application of the Company’s available Federal and State net operating loss (NOL) carryforwards that are available to reduce taxable income. As of June 30, 2026 and 2025, a reconciliation of the Company’s effective income tax rate to the U.S. statutory and its deferred tax assets are as follows: <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2euAllshnXg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Tax reconciliation)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of reconciliation of effective income tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended Jun 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Tax benefit (expense) at the federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_marate2026_c20250701__20260630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrvBV5BvAcHk" style="width: 11%; text-align: right">294,000</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mapercent2026_c20250701__20260630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zPnGEUf7FM8g" style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240701__20250630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWvpw7TCgq29" style="width: 11%; text-align: right">24,000</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240701__20250630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmZWzJtv2fDd" style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of Federal benefit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_marate2026_c20250701__20260630_zC4zNlAUWqKb" style="text-align: right">98,000</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mapercent2026_c20250701__20260630_z5YrL5tly8Eh" style="text-align: right">7%</td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20240701__20250630_zd7FVFNK67Zi" style="text-align: right">8,000</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240701__20250630_zsuCu33O1jH5" style="text-align: right">7%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Prior year net operating loss true up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right">–%</td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_c20240701__20250630_zoM3ZHbwak49" style="text-align: right">9,000</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240701__20250630_zCu1vRgArWmh" style="text-align: right">8%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_marate2026_c20250701__20260630_zQSC5MV0lSAh" style="border-bottom: Black 1pt solid; text-align: right">(392,000</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mapercent2026_c20250701__20260630_z0iXo4cp9Hj" style="border-bottom: Black 1pt solid; text-align: right">(28%</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240701__20250630_zLC2Mfi9a31i" style="border-bottom: Black 1pt solid; text-align: right">(41,000</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240701__20250630_z0ZXSPEysLa8" style="border-bottom: Black 1pt solid; text-align: right">(36%</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtrate2026_c20250701__20260630_zh5EJJIfLyI5" style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">–%</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_c20240701__20250630_zgsi8cK00ve4" style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">–%</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The components of deferred tax assets are presented below. At June 30, 2026, the Company had available Federal NOL carryforwards of approximately $12.0 million that are available to reduce future taxable income. The Federal NOL carry forward of approximately $8.5 million expires through 2037, the remaining NOL of $3.5 million has no expiry date. The NOLs are subject to statutory limitations under Internal Revenue Code Section 382 regarding substantial changes in ownership of companies with loss carry forwards. At June 30, 2026 and 2025, significant component of the Company’s deferred tax assets and liabilities are as follows: <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zBSbPTvkILAd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Deferred tax assets and liabilities)"> <tr style="vertical-align: bottom"> <td>Schedule of deferred tax assets and liabilities</td><td> </td> <td colspan="2" id="xdx_49A_20260630_zXNmBiymaf7l" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20250630_zrCeTsIz9Cs2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmJt_zAhP7hoUDmg7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Net Operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">3,163,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,956,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmJt_ztR37zRYaBS9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Stock compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,203,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,018,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmJt_maDTANzoSd_zNkUiLU1haE3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total net deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,366,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,974,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzoSd_zqsRnfPt9Ae6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,366,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANzoSd_z11RtrcTCk34" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The provisions of ASC Topic 740, Accounting for Income Taxes, require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. For the years ended June 30, 2026 and 2025, based on all available objective evidence, including the existence of cumulative losses, the Company determined that it was more likely than not that the net deferred tax assets were not fully realizable. Accordingly, the Company established a full valuation allowance against its net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. Accounting rules prescribe a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid. The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized. Our income tax filings are periodically examined by various U.S. federal and state jurisdictions. There are no open examinations by federal and state income tax jurisdictions. The Company’s U.S. federal income tax return remains open to examination for the years ended June 30, 2023 through June 30, 2026.

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2euAllshnXg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Tax reconciliation)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of reconciliation of effective income tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended Jun 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Tax benefit (expense) at the federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_marate2026_c20250701__20260630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrvBV5BvAcHk" style="width: 11%; text-align: right">294,000</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mapercent2026_c20250701__20260630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zPnGEUf7FM8g" style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20240701__20250630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWvpw7TCgq29" style="width: 11%; text-align: right">24,000</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20240701__20250630__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmZWzJtv2fDd" style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of Federal benefit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_marate2026_c20250701__20260630_zC4zNlAUWqKb" style="text-align: right">98,000</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mapercent2026_c20250701__20260630_z5YrL5tly8Eh" style="text-align: right">7%</td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20240701__20250630_zd7FVFNK67Zi" style="text-align: right">8,000</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240701__20250630_zsuCu33O1jH5" style="text-align: right">7%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Prior year net operating loss true up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right">–%</td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_c20240701__20250630_zoM3ZHbwak49" style="text-align: right">9,000</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240701__20250630_zCu1vRgArWmh" style="text-align: right">8%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_marate2026_c20250701__20260630_zQSC5MV0lSAh" style="border-bottom: Black 1pt solid; text-align: right">(392,000</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mapercent2026_c20250701__20260630_z0iXo4cp9Hj" style="border-bottom: Black 1pt solid; text-align: right">(28%</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20240701__20250630_zLC2Mfi9a31i" style="border-bottom: Black 1pt solid; text-align: right">(41,000</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240701__20250630_z0ZXSPEysLa8" style="border-bottom: Black 1pt solid; text-align: right">(36%</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtrate2026_c20250701__20260630_zh5EJJIfLyI5" style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">–%</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_c20240701__20250630_zgsi8cK00ve4" style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">–%</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

294000

0.21

24000

0.21

98000

0.07

8000

0.07

9000

0.08

-392000

-0.28

-41000

-0.36

12000000.0

8500000

3500000

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zBSbPTvkILAd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Deferred tax assets and liabilities)"> <tr style="vertical-align: bottom"> <td>Schedule of deferred tax assets and liabilities</td><td> </td> <td colspan="2" id="xdx_49A_20260630_zXNmBiymaf7l" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20250630_zrCeTsIz9Cs2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmJt_zAhP7hoUDmg7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Net Operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">3,163,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,956,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmJt_ztR37zRYaBS9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Stock compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,203,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,018,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmJt_maDTANzoSd_zNkUiLU1haE3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total net deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,366,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,974,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzoSd_zqsRnfPt9Ae6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,366,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANzoSd_z11RtrcTCk34" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3163000

2956000

1203000

1018000

4366000

3974000

4366000

3974000

Note 11 – Related Party Transactions Accrued Payroll and Payroll Taxes The Company accrues salaries and estimated payroll taxes due to a former officer and current shareholder and current officer and director of the Company. As of June 30, 2024, the total accrued payroll and payroll taxes amounted to $414,000. In February 2025, the Company settled with these former officer and current officer to extinguish the accrued payroll and payroll related taxes amounting to $425,000 and unpaid health insurance and cellphone reimbursements recorded in prior years totaling $36,000 for a total liability of $461,000. As part of the settlement, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20250201__20250228__us-gaap--RelatedPartyTransactionAxis__custom--SettlementOfAccruedPayrollMember_zsJITM99eDai" title="Stock issued for compensation, shares">4,666,600 shares of common stock with a fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20250201__20250228__us-gaap--RelatedPartyTransactionAxis__custom--SettlementOfAccruedPayrollMember_zWSAhXwu8a7d" title="Stock issued for compensation, value">90,000 and warrants to purchase 5,000,000 shares of common stock. The warrants are fully vested, exercisable at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250228__us-gaap--RelatedPartyTransactionAxis__custom--SettlementOfAccruedPayrollMember_zDg69sIe22Hg" title="Warrants exercise price">0.016 per share and will expire in five years. The estimated fair value of these warrants amounted to $100,000 using the Black Scholes Option Pricing Model using the following inputs (i) stock price at the date of grant of $0.020; (ii) risk free interest rate of 4.37% based on rates established by the Federal Reserve Bank; (iii) expected volatility 290% based on historical volatility of the Company’s common stock commensurate with the expected life of the warrants; (iv) expected life of 5 years based on the contractual life; and (v) dividend yield of 0% based on no dividends paid or expected to be paid. Pursuant to current accounting and SEC guidelines and regulations with regards to related party transactions, the Company accounted for the difference of $271,000 between the carrying amount of the accrued payroll and other liability of $461,000 and the fair value of the common stock and warrants issued of $190,000 as capital contribution. As of June 30, 2025, there was no accrued payroll and payroll related taxes. As of June 30, 2026, the total accrued salary and payroll related taxes amounted to $129,000. Consulting Fees The Company recognized consulting fees to a member of the Company’s Board of Directors amounting to $5,000 for the years ended June 30, 2025. There was no consulting fee recognized to directors and officers for the year ended June 30, 2026.

414000

4666600

90000

5000000

0.016

100000

129000

5000

Note 12 – Segment Information The Company operates and manages its business as one reportable and operating segment. The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance. Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate the business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zJ4RcNkH8pxb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of segment information</td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20250701__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zw4CTQdqpTX7" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zLlN20eQzvv8" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_d0_z5kvbSWvNvVa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">3,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">203,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CostOfRevenue_iN_di0_zhBSFR53mzDe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(38,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--GrossProfit_d0_zmhTAGHFBbX7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">165,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zYZstPAq6QLl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(95,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_iN_di_zQGhGo37S9R" style="vertical-align: bottom; background-color: White"> <td>Salaries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(493,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(471,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_zvp9kuzQz9C1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ProfessionalFees_iN_di_zWLu9bqPC6q1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(171,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(168,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_iN_di_zTQvTQYJCUy2" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Rent expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--TravelAndEntertainmentExpense_iN_di0_zxCD05Cmqnm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(56,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_iN_di_zNCbtzwaEhql" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(394,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(201,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--OtherOperatingExpenses_iN_di_zqhMg5e1aOY4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(129,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(91,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iN_di_zR1y4RELhFhj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Total operating expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,391,000</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,152,000</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zQ6Mb5gZGPz7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Net operating loss</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,388,000</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(987,000</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfIntangibleAssets_d0_zWCAqKQt46Kh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Gain on patent assignment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">880,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_iN_di_zJqcBeybPIQe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest and other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--DerivativeLiabilityMovement_iN_di0_zN5NSNGmyBT1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zobz3FuSqgT5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,404,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(113,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zJ4RcNkH8pxb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of segment information</td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20250701__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zw4CTQdqpTX7" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zLlN20eQzvv8" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_d0_z5kvbSWvNvVa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">3,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">203,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CostOfRevenue_iN_di0_zhBSFR53mzDe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(38,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--GrossProfit_d0_zmhTAGHFBbX7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">165,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zYZstPAq6QLl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(95,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_iN_di_zQGhGo37S9R" style="vertical-align: bottom; background-color: White"> <td>Salaries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(493,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(471,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_zvp9kuzQz9C1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ProfessionalFees_iN_di_zWLu9bqPC6q1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(171,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(168,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_iN_di_zTQvTQYJCUy2" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Rent expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--TravelAndEntertainmentExpense_iN_di0_zxCD05Cmqnm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(56,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_iN_di_zNCbtzwaEhql" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(394,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(201,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--OtherOperatingExpenses_iN_di_zqhMg5e1aOY4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(129,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(91,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iN_di_zR1y4RELhFhj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Total operating expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,391,000</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,152,000</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zQ6Mb5gZGPz7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Net operating loss</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,388,000</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(987,000</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfIntangibleAssets_d0_zWCAqKQt46Kh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Gain on patent assignment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">880,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_iN_di_zJqcBeybPIQe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest and other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--DerivativeLiabilityMovement_iN_di0_zN5NSNGmyBT1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zobz3FuSqgT5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,404,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(113,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table>

3000

203000

-0

38000

3000

165000

11000

95000

493000

471000

101000

67000

171000

168000

36000

29000

56000

30000

394000

201000

129000 91000

1391000

1152000

-1388000

-987000

880000

40000

6000

-24000 -0

-1404000

-113000

Note 13 – Subsequent events Common Share issuances During August 2026, The Company entered into agreements with five accredited investors, whereby gross proceeds of $140,000 was received for the issuance of 4,666,665 shares of common stock at an issue price of $0.03 per share. In addition, three accredited investors agreed to cancel warrants issuable for 2,499,999 shares of common stock at an exercise price of $0.045 per share. Warrants exercised On September 10, 2026, a warrant holder exercised a warrant for 3,000,000 shares of common stock on a cashless basis. The warrant exercise price was $0.017 per share. The market price used in the calculation was $0.0478 per share on September 10, 2026, resulting in the issuance of 1,933,055 shares of common stock. Other than disclosed above, the Company has evaluated subsequent events through the date the financial statements were issued and did not identify any additional subsequent events that would have required adjustment or disclosure in the financial statements.

false false false false false We do not grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. true